150 related articles for article (PubMed ID: 37653461)
1. Initiatives to promote access to medicines after publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases.
Cunico C; Vicente G; Leite SN
Orphanet J Rare Dis; 2023 Aug; 18(1):259. PubMed ID: 37653461
[TBL] [Abstract][Full Text] [Related]
2. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
3. [Rare diseases in the Brazilian National Congress: analysis of parliamentary action].
Pascarelli DBN; Pereira ÉL
Cad Saude Publica; 2022; 38(6):e00167721. PubMed ID: 35857920
[TBL] [Abstract][Full Text] [Related]
4. Corporate social responsibility to improve access to medicines: the case of Brazil.
Thorsteinsdóttir H; Ovtcharenko N; Kohler JC
Global Health; 2017 Feb; 13(1):10. PubMed ID: 28222793
[TBL] [Abstract][Full Text] [Related]
5. Judicialization and right to health in Brazil: a trajectory of matches and mismatches.
Vieira FS
Rev Saude Publica; 2023; 57():1. PubMed ID: 36820680
[TBL] [Abstract][Full Text] [Related]
6. [Consequences of the judicialization of health policies: the cost of medicines for mucopolysaccharidosis].
Diniz D; Medeiros M; Schwartz IV
Cad Saude Publica; 2012 Mar; 28(3):479-89. PubMed ID: 22415180
[TBL] [Abstract][Full Text] [Related]
7. Judicialization of medicines: effectiveness of rights or break in public policies?
Oliveira YMDC; Braga BSF; Farias AD; Pereira SPD; Ferreira MAF
Rev Saude Publica; 2020; 54():130. PubMed ID: 33331524
[TBL] [Abstract][Full Text] [Related]
8. Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.
Garcia MM; Azevedo PS; Mirelman A; Safatle LP; Iunes R; Bennie MC; Godman B; Guerra Junior AA
Front Pharmacol; 2020; 11():370. PubMed ID: 32351382
[TBL] [Abstract][Full Text] [Related]
9. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil.
Biehl J; Amon JJ; Socal MP; Petryna A
Health Hum Rights; 2012 Jun; 14(1):E36-52. PubMed ID: 22773096
[TBL] [Abstract][Full Text] [Related]
10. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
11. Availability of Genetic Tests in Public Health Services in Brazil: Data from the Brazilian Rare Diseases Network.
de Oliveira BM; Neiva MB; Carvalho I; Schwartz IVD; Alves D; Felix TM;
Public Health Genomics; 2023; 26(1):145-158. PubMed ID: 37356424
[TBL] [Abstract][Full Text] [Related]
12. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN).
Félix TM; de Oliveira BM; Artifon M; Carvalho I; Bernardi FA; Schwartz IVD; Saute JA; Ferraz VEF; Acosta AX; Sorte NB; Alves D;
Orphanet J Rare Dis; 2022 Feb; 17(1):84. PubMed ID: 35209917
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of drugs for rare diseases in Brazil: is it possible to have full access to these patients?
Biglia LV; Mendes SJ; Lima TM; Aguiar PM
Cien Saude Colet; 2021 Nov; 26(11):5547-5560. PubMed ID: 34852089
[TBL] [Abstract][Full Text] [Related]
15. Rare essentials: drugs for rare diseases as essential medicines.
Stolk P; Willemen MJ; Leufkens HG
Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
[TBL] [Abstract][Full Text] [Related]
16. Prison pharmaceutical care in the State of Pará, Brazil: determining factors for access to medicines and the right to health.
Costa APAM; Soler O; Queiroz LMD
Cien Saude Colet; 2022 Dec; 27(12):4579-4588. PubMed ID: 36383871
[TBL] [Abstract][Full Text] [Related]
17. Access to medicines: relations with the institutionalization of pharmaceutical services.
Barros RD; Costa EA; Santos DBD; Souza GS; Álvares J; Guerra AA; Acurcio FA; Guibu IA; Costa KS; Karnikowski MGO; Soeiro OM; Leite SN
Rev Saude Publica; 2017 Nov; 51(suppl 2):8s. PubMed ID: 29160462
[TBL] [Abstract][Full Text] [Related]
18. Administrative cases: an effective alternative to lawsuits in assuring access to medicines?
Chagas VO; Provin MP; Amaral RG
BMC Public Health; 2019 Feb; 19(1):212. PubMed ID: 30786892
[TBL] [Abstract][Full Text] [Related]
19. Free access to medicines for the treatment of chronic diseases in Brazil.
Tavares NU; Luiza VL; Oliveira MA; Costa KS; Mengue SS; Arrais PS; Ramos LR; Farias MR; Pizzol TD; Bertoldi AD
Rev Saude Publica; 2016 Dec; 50(suppl 2):7s. PubMed ID: 27982374
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
